These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 1820342)

  • 1. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
    Wolf CR
    IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the primary gene defect at the cytochrome P450 CYP2D locus.
    Gough AC; Miles JS; Spurr NK; Moss JE; Gaedigk A; Eichelbaum M; Wolf CR
    Nature; 1990 Oct; 347(6295):773-6. PubMed ID: 1978251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the cytochrome P450 isozyme that metabolizes ochratoxin A, using metabolic inducers, inhibitors and antibodies.
    Hietanen E; Bartsch H; Béréziat JC; Castegnaro M; Michelon J
    IARC Sci Publ; 1991; (115):297-304. PubMed ID: 1820345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor.
    Nikolov IG; Chernozemsky IN; Idle JR
    IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility.
    Smith CA; Moss JE; Gough AC; Spurr NK; Wolf CR
    Environ Health Perspect; 1992 Nov; 98():107-12. PubMed ID: 1486838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens.
    Caporaso N
    Ann Ist Super Sanita; 1991; 27(4):621-30. PubMed ID: 1820735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics and human cancer.
    Nebert DW
    IARC Sci Publ; 1982; (39):365-80. PubMed ID: 7152614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Environmental and chemical carcinogenesis.
    Wogan GN; Hecht SS; Felton JS; Conney AH; Loeb LA
    Semin Cancer Biol; 2004 Dec; 14(6):473-86. PubMed ID: 15489140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal tumorigenicity of 1,1-dichloroethene in mice: the role of male-specific expression of cytochrome P450 2E1 in the renal bioactivation of 1,1-dichloroethene.
    Speerschneider P; Dekant W
    Toxicol Appl Pharmacol; 1995 Jan; 130(1):48-56. PubMed ID: 7839370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.
    Tyndale RF; Sunahara R; Inaba T; Kalow W; Gonzalez FJ; Niznik HB
    Mol Pharmacol; 1991 Jul; 40(1):63-8. PubMed ID: 1857341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex- and strain-specific expression of cytochrome P450s in ochratoxin A-induced genotoxicity and carcinogenicity in rats.
    Pfohl-Leszkowicz A; Pinelli E; Bartsch H; Mohr U; Castegnaro M
    Mol Carcinog; 1998 Oct; 23(2):76-85. PubMed ID: 9808161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the cytochrome P450 system as a mechanism of chemoprotection.
    Wolf CR; Mahmood A; Henderson CJ; McLeod R; Manson MM; Neal GE; Hayes JD
    IARC Sci Publ; 1996; (139):165-73. PubMed ID: 8923029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentrations of ochratoxin A in the urine of endemic nephropathy patients and controls in Bulgaria: lack of detection of 4-hydroxyochratoxin A.
    Castegnaro M; Maru V; Petkova-Bocharova T; Nikolov I; Bartsch H
    IARC Sci Publ; 1991; (115):165-9. PubMed ID: 1820331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic polymorphisms and cancer susceptibility.
    Smith G; Stanley LA; Sim E; Strange RC; Wolf CR
    Cancer Surv; 1995; 25():27-65. PubMed ID: 8718512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility.
    Badawi AF; Stern SJ; Lang NP; Kadlubar FF
    Prog Clin Biol Res; 1996; 395():109-40. PubMed ID: 8895986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk.
    Nebert DW
    Cancer Cells; 1991 Mar; 3(3):93-6. PubMed ID: 2054261
    [No Abstract]   [Full Text] [Related]  

  • 18. Interstrain comparison of hepatic and renal microsomal carcinogen metabolism and liver S9-mediated mutagenicity in DA and Lewis rats phenotyped as poor and extensive metabolizers of debrisoquine.
    Hietanen E; Malaveille C; Camus AM; Béréziat JC; Brun G; Castegnaro M; Michelon J; Idle JR; Bartsch H
    Drug Metab Dispos; 1986; 14(1):118-26. PubMed ID: 2868854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.
    Zhou-Pan XR; Sérée E; Zhou XJ; Placidi M; Maurel P; Barra Y; Rahmani R
    Cancer Res; 1993 Nov; 53(21):5121-6. PubMed ID: 8221648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human cytochrome P4501A2.
    Landi MT; Sinha R; Lang NP; Kadlubar FF
    IARC Sci Publ; 1999; (148):173-95. PubMed ID: 10493258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.